#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Alport's syndrome Allogenic stem cell transplantation Duchenne muscular dystrophy gene carrier Autoinflammation with infantile enterocolitis Ovarian cancer stage III Leber's congenital amaurosis Osteogenesis imperfecta Mucopolysaccharidosis II Mucopolysaccharidosis III Diffuse large B-cell lymphoma refractory Congenital cystic kidney disease Polymyositis Hypomagnesaemia Myotonia Prolymphocytic leukaemia More trials…

    Learn about Rare Diseases

    Glycogen storage disease type I – Trials in Disease Tuberous sclerosis complex – Life with Disease Shprintzen-Goldberg syndrome – Diagnostics Glycogen storage disease type II – Diagnostics Mantle cell lymphoma stage III Encephalitis autoimmune – Diagnostics Pulmonary sarcoidosis – Life with Disease Haemophilia B with anti factor IX – Basic Information Synovial sarcoma – Diagnostics Rhabdomyosarcoma recurrent – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    VELPATASVIR Oteracil TAGRAXOFUSP Amikacin Sulfate Gadoteridol Pitavastatin Calcium Tislelizumab Atogepant Tulisokibart ORG-129 PROMESTRIENE ETX-19477 Protamine Sulfate Loperamide Hydrochloride Lonapegsomatropin RNMB3 Ly3437943 Sodium Isavuconazonium Sulfate Oxaliplatin Rivaroxaban More therapies…

    Learn about Your Condition

    Major depression Hand dermatitis Burning mouth syndrome Dupuytren's contracture Follicular lymphoma stage III Gastrointestinal melanoma Pancreatic carcinoma stage IV Arteriovenous graft thrombosis Liposarcoma recurrent Double hit lymphoma Nephrogenic anaemia Hereditary angioedema Rectal cancer stage II Pulmonary alveolar haemorrhage Factor VIII deficiency More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Feasibility of Sequential Radium Ra-223 Dichloride After Triplet Therapy in High‑Volume Metastatic Hormone‑Sensitive Prostate Cancer Patients (Phase II)

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Radium Ra 223 Dichloride
    Spain

  • Advanced hepatocellular carcinoma patients: assessing atezolizumab drug combination and other treatment sequences

    Not yet recruiting

    4 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Cabozantinib
    • Regorafenib
    • Sorafenib
    Italy

  • Phase II Study of [68Ga]Ga-FAP-2286 PET/CT for Staging and Restaging Newly Diagnosed Primary Breast Cancer Patients

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Breast cancer
    Denmark

  • Study of dupilumab added to standard care in adults hospitalized for COPD exacerbation to reduce readmissions, emergency visits, and death

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Dupilumab
    Belgium Italy Spain

  • Evaluation of zongertinib, fulvestrant and goserelin acetate in patients with HR‑positive HER2‑negative advanced breast cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Breast cancer
    Investigated Drugs:
    • Goserelin Acetate
    • Zongertinib
    • Fulvestrant
    Germany Italy Spain

  • Safety, tolerability and efficacy of XEN-D0501 in adults with obesity

    Not yet recruiting

    1 1
    Investigated Diseases:
    • Obesity
    Sweden
Previous Page
1 … 664 665 666 667 668 … 1,656
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!